实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (5): 789-792.doi: 10.3969/j.issn.1672-5069.2026.05.038

• 胆管癌 • 上一篇    下一篇

内镜逆行胰胆管造影和经皮肝穿刺胆道引流姑息性治疗肝门部胆管癌患者临床疗效研究*

李文静, 汪奕慧, 马韩婷, 孙杰   

  1. 214000 江苏省无锡市 解放军联勤保障部队第904医院普外科(李文静,马韩婷);江苏省宿迁市宿城区龙河人民医院急诊科(汪奕慧);江南大学附属医院普外科(孙杰)
  • 收稿日期:2025-11-10 发布日期:2026-09-14
  • 作者简介:李文静,女,31岁,大学本科。E-mail:13506181809@163.com
  • 基金资助:
    江苏省自然科学基金资助项目(编号:BK20240500)

Palliative treatment of patients with hilar cholangiocarcinoma and obstructive jaundice: Effectiveness comparison of endoscopic retrograde cholangiopancreatography vs. percutaneous transhepatic cholangiographic drainage

Li Wenjing, Wang Yihui, Ma Hanting, et al   

  1. Department of General Surgery, 904th Hospital, Joint Logistics Support Force, Wuxi 214000, Jiangsu Province, China
  • Received:2025-11-10 Published:2026-09-14

摘要: 目的 分析比较内镜逆行胰胆管造影(ERCP)与经皮肝穿刺胆道引流(PTCD)姑息性引流治疗肝门部胆管癌(HiCC)患者的疗效。方法 2022年1月~2024年12月我院诊治的因无法手术切除且引起梗阻性黄疸的HiCC患者56例,其中接受ERCP治疗30例,接受PTCD治疗26例。采用ELISA法检测血清C-反应蛋白(CRP)和白细胞介素-6(IL-6)水平,使用流式细胞仪检测外周血淋巴细胞亚群,计算CD4+/CD8+细胞比值。结果 在术后7 d,ERCP治疗组引流管通畅率为93.3%,显著高于PTCD治疗组的76.9%(P<0.05),血清总胆红素水平为(79.3±23.5)μmol/L,显著低于PTCD治疗组【(98.6±26.7)μmol/L,P<0.05】,而血清白蛋白水平为(37.8±5.9)g/L,显著高于PTCD治疗组【(34.3±6.1)g/L,P<0.05】;术后ERCP组并发症发生率为20.0%,显著低于PTCD组的46.2%(P<0.05);在术后14 d,ERCP组血清CRP和IL-6水平均显著低于,外周血CD4+细胞百分比和和CD4+/CD8+细胞比值均显著高于PTCD组(P<0.05);ERCP治疗组KPS评分和食欲改善率均显著高于PTCD治疗组(P<0.05);ERCP治疗组中位生存期和12 m生存率分别为9.8(8.4,11.3)m和43.3%,均显著长于或高于PTCD治疗组【分别为7.2(6.1,8.4)m和26.9%,P<0.05】。结论 采取ERCP和PTCD处理HiCC患者均可有效减黄,而ERCP治疗似可取得更好的治疗效果。

关键词: 肝门部胆管癌, 梗阻性黄疸, 内镜逆行胰胆管造影术, 经皮肝穿刺胆道引流术, 治疗

Abstract: Objective This study aimed to retrospectively compare clinical efficacy of endoscopic retrograde cholangiopancreatography (ERCP) vs. percutaneous transhepatic cholangial drainage (PTCD in dealing with patients with hilar cholangiocarcinoma (HiCC) and obstructive jaundice. Methods 56 patients with unresectable HiCC with hyperbilirubinemia were encountered in our hospital between January 2022 and December 2024, of them, ERCP was conducted in 30 cases and PTCD in 26 cases. Serum C-reactive protein (CRP) and interleukin-6 (IL-6) levels were detected by ELISA, and peripheral blood lymphocyte subsets were determined by FCM. Short-term quality of life was assessed by KPS score. Results By end of 7 days after operation, drainage tube patency in ERCP group was 93.3%,much higher than 76.9%(P<0.05), total serum bilirubin level was (79.3±23.5)μmol/L, much lower than [(98.6±26.7)μmol/L,P<0.05],while serum albumin level was (37.8±5.9)g/L, much higher than [(34.3±6.1)g/L,P<0.05] in PTCD group; incidence of post-operational complications was 20.0%,much lower than 46.2%(P<0.05) in PTCD group; by end of 14 days after surgery, serum CRP and IL-6 levels were both significantly lower than, while peripheral blood CD4+ cell percentage and CD4+/CD8+ cell ratio were both significantly higher than in PTCD group(P<0.05);KPS score and improvement of appetite were much higher than in PTCD group(P<0.05);median overall survival and 12 m survival rate were 9.8(8.4,11.3)mon and 43.3%,both much longer or higher than [7.2(6.1,8.4)mon and 26.9%,P<0.05] in PTCD group. Conclusion Both ERCP and PTCD could effectively relieve malignant obstructive jaundice in patients with HiCC, but we recommend ERCP preferentially as it seems more efficacious.

Key words: Hilar cholangiocarcinoma, Obstructive jaundice, Endoscopic retrograde cholangiopancreatography, Percutaneous transhepatic cholangial drainage, Therapy